 |
Locate Clinical Trials Being Conducted in a Particular Year on a Specific Drug?
TOPIC: In this example, using four biomedical databases—MEDLINE® (File 154), EMBASE® (File 72), BIOSIS Previews® (File 55) and SciSearch®: A Cited Reference Database (File 34)—you want to find recent clinical trials for the drug Infliximab, a drug used to treat rheumatoid arthritis.
All four databases are central to biomedical research; however, as the example shows, they are searched differently. Both MEDLINE and EMBASE have their own thesaurus to help in locating search terms. In these two databases, you will use the EXPLODE command (!) to select all narrower terms for clinical trials quickly and easily. In BIOSIS and SciSearch, you want to use as many keyword synonyms as possible to conduct the search.
COMMAND SUMMARY
BEGIN 154,72,55,34
SELECT INFLIXIMAB/TI,DE AND DT=(CLINICAL? OR MULTICENTER? OR RANDOMIZED? OR META? OR CONTROLLED?) OR CLINICAL TRIALS! FROM 154
SELECT INFLIXIMAB(L)CT OR (INFLIXIMAB/TI,DE AND CLINICAL TRIAL!) FROM 72
SELECT INFLIXIMAB/TI,DE,ID AND ((CLINICAL OR RANDOMI? OR CONTROLLED)(1W)(TRIAL OR STUDY OR STUDIES) OR MULTICENTER OR META()ANALYS? OR PHASE(W) (I OR II OR III OR 1 OR 2 OR 3)) FROM 55,34
SELECT S1 OR S2 OR S3
SELECT S4/2006
RD
TYPE S6/6/1 FROM EACH
TYPE S6/9/4889
HOW TO...
1. BEGIN 154, 72, 55, 34 to search key biomedical databases.
2. Create a search statement for MEDLINE using:
- Document types (DT=)
- Suffixes for title (/TI) and descriptors (/DE)
- EXPLODE (!) to retrieve all phases of clinical trials
- FROM 154 to search just MEDLINE
3. Create a search statement for EMBASE using:
- (L) connector to connect heading and subheading for clinical trial (CT)
- Suffixes for title (/TI) and descriptors (/DE)
- EXPLODE (!) to retrieve all phases of clinical trials
- FROM 72 to search only EMBASE
|
?b 154,72,55,34
SYSTEM:OS - DIALOG OneSearch
File 154:MEDLINE(R) 1990-2006/Aug 23
(c) format only 2006 Dialog
File 72:EMBASE 1993-2006/Aug 24
(c) 2006 Elsevier B.V.
File 55:Biosis Previews(R) 1993-2006/Aug W3
(c) 2006 The Thomson Corporation
File 34:SciSearch(R) Cited Ref Sci 1990-2006/Aug W3
(c) 2006 The Thomson Corp
Set Items Description
--- ----- -----------
?S INFLIXIMAB/TI,DE AND DT=(CLINICAL? OR MULTICENTER? OR RANDOMIZED? OR META? OR CONTROLLED?) OR CLINICAL TRIALS! FROM 154
1254 INFLIXIMAB/TI,DE
323747 DT=CLINICAL?
73433 DT=MULTICENTER?
176466 DT=RANDOMIZED?
13180 DT=META?
39868 DT=CONTROLLED?
109348 CLINICAL TRIALS!
S1 109585 INFLIXIMAB/TI,DE AND DT=(CLINICAL? OR MULTICENTER? OR RANDOMIZED? OR META? OR CONTROLLED?) OR CLINICAL
TRIALS! FROM 154
?S INFLIXIMAB(L)CT OR (INFLIXIMAB/TI,DE AND CLINICAL TRIAL!) FROM 72
6188 INFLIXIMAB/DE
234680 CT/DE
1421 INFLIXIMAB/DE(L)CT/DE
6236 INFLIXIMAB/TI,DE
396144 CLINICAL TRIAL!
S2 2450 INFLIXIMAB(L)CT OR (INFLIXIMAB/TI,DE AND CLINICAL TRIAL!) FROM 72 |
4. Create a search statement for BIOSIS and SciSearch using:
- Suffixes for title (/TI), descriptors (/DE) and identifiers (ID)
- Synonyms for clinical trials, remembering to put ORed terms in parentheses
- FROM 55,34 to search both BIOSIS and SciSearch
|
?SELECT INFLIXIMAB/TI,DE,ID AND ((CLINICAL OR RANDOMI? OR CONTROLLED)(1W)(TRIAL OR STUDY OR STUDIES) OR MULTICENTER OR META()ANALYS? OR PHASE(W) (I OR II OR III OR 1 OR 2 OR 3)) FROM 55,34
Processing
5826 INFLIXIMAB/TI,DE,ID
2124852 CLINICAL
337020 RANDOMI?
527017 CONTROLLED
445001 TRIAL
4189217 STUDY
2266830 STUDIES
356851 ((CLINICAL OR RANDOMI?) OR CONTROLLED)(1W)((TRIAL OR STUDY) OR STUDIES)
66671 MULTICENTER
43371 META
3532039 ANALYS?
25807 META(W)ANALYS?
1276603 PHASE
1849962 I
1022167 II
446089 III
5877130 1
5632591 2
4278628 3
105743 PHASE(W)(((((I OR II) OR III) OR 1) OR 2) OR 3)
S3 978 INFLIXIMAB/TI,DE,ID AND ((CLINICAL OR RANDOMI? OR CONTROLLED)(1W)(TRIAL OR STUDY OR STUDIES) OR MULTICENTER OR META()ANALYS? OR PHASE(W) (I OR II OR III OR 1 OR 2 OR 3)) FROM 55,34 |
5. Combine the three sets using OR and narrow to the current year.
6. REMOVE DUPLICATES (RD) when searching more than one database.
|
?S S1 OR S2 OR S3
109585 S1
2450 S2
978 S3
S4 113013 S1 OR S2 OR S3
?S S4/2006
113013 S4
1574103 PY=2006
S5 5054 S4/2006
?RD
Processing - Examined 5000 records
S6 4948 RD (unique items) |
7. TYPE titles using Format 6 and FROM EACH to identify records in each database to view in more detail.
You can review toxicology literature on this drug or display all or parts of the record. |
?T S6/6/1-2 FROM EACH
6/6/1 (Item 1 from file: 154)
21431574 PMID: 16912269
Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Aug 16 2006
6/6/4603 (Item 1 from file: 72)
13963433 EMBASE No: 2006388890
Gateways to clinical trials: July/August 2006
2006
6/6/4889 (Item 3 from file: 55)
0016057692 BIOSIS NO.: 200600403087
The safety of infliximab , combined with background treatments, among patients with rheumatoid arthritis and various comorbidities - A large, randomized, placebo- controlled trial
2006
6/6/4899 (Item 3 from file: 34)
15394041 Genuine Article#: 065EE Number of References: 49
Title: Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis (ABSTRACT AVAILABLE)
Publication date: 20060000 |
8. For complete records TYPE in Format 9. Note the number of the record you are displaying (4889). |
?T S6/9/4889
6/9/4889 (Item 3 from file: 55)
DIALOG(R)File 55:Biosis Previews(R)
(c) 2006 The Thomson Corporation. All rts. reserv.
0016057692 BIOSIS NO.: 200600403087
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities - A large, randomized, placebo-controlled trial
AUTHOR: START Study Grp
AUTHOR ADDRESS: UZ Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium**
Belgium
JOURNAL: Arthritis & Rheumatism 54 (4): p1075-1086 APR 2006 2006
ISSN: 0004-3591
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
ABSTRACT: Objective. To assess the risk of serious infections following 22 weeks of infliximab therapy, and to further characterize the safety profile of infliximab in combination with background treatments during 1 year in patients with rheumatoid arthritis (RA) with various comorbidities.Methods. Patients with active RA despite receiving methotrexate (MTX) were randomly assigned to receive infusions of placebo (group 1, n = 363), 3 mg/kg infliximab (group 2, n = 360), or 10 mg/kg infliximab (group 3, n = 361) at weeks 0, 2, 6, and 14. At week 22, patients in placebo group I began receiving 3 mg/kg infliximab, and
patients in group 3 continued to receive an infliximab dose of 10 mg/kg.
Patients in group 2 who failed to meet predefined response criteria received increasing doses of infliximab in increments of 1.5 mg/kg.Results. At week 22, the relative risk of developing serious infections in groups 2 and 3, compared with group 1, was 1.0 (95% confidence interval [95% CI] 0.3-3.1, P = 0.995) and 3.1 (95% CI 1.2-7.9, P = 0.013), respectively. The incidence of serious adverse events was 7.8% in groups 2 and 3 compared with 7.5% in group 1. From week 22 to week 54, 11.8%, 9.9%, and 10.3% of patients in groups 1, 2, and 3, respectively, reported occurrences of serious adverse events. Through week 54, 1 patient in group 1, 2 patients in group 2, and 4 patients in group 3 developed active tuberculosis.Conclusion. The risk of serious
infections in patients receiving the approved infliximab dose of 3 mg/kg plus MTX was similar to that in patients receiving MTX alone. Patients receiving the unapproved induction regimen of 10 mg/kg infliximab plus MTX followed by a 10 mg/kg maintenance regimen had an increased risk of serious infections through week 22.
REGISTRY NUMBERS: 59-05-2: methotrexate; 170277-31-3: infliximab DESCRIPTORS:
MAJOR CONCEPTS: Pharmacology; Clinical Immunology--Human Medicine, Medical Sciences; Infection; Rheumatology--Human Medicine, Medical Sciences
BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGANISMS: human (Hominidae)--female, male
COMMON TAXONOMIC TERMS: Animals; Chordates; Humans; Mammals; Primates; Vertebrates
DISEASES: tuberculosis--bacterial disease; infection--infectious disease, etiology; rheumatoid arthritis--immune system disease, joint disease, connective tissue disease, drug therapy, complications
MESH TERMS: Tuberculosis (MeSH); Infection (MeSH); Arthritis, Rheumatoid (MeSH)
CHEMICALS & BIOCHEMICALS: methotrexate--enzyme inhibitor-drug, antiarthritic-drug, immunologic-drug, antiinflammatory-drug; infliximab--immunologic-drug, antiarthritic-drug, adverse effects, drug safety
MISCELLANEOUS TERMS: comorbidity; drug regime
CONCEPT CODES:
10060 Biochemistry studies - General
12512 Pathology - Therapy
18006 Bones, joints, fasciae, connective and adipose tissue - Pathology
22002 Pharmacology - General
22005 Pharmacology - Clinical pharmacology
22012 Pharmacology - Connective tissue, bone and collagen-acting drugs
22018 Pharmacology - Immunological processes and allergy
22504 Toxicology - Pharmacology
34508 Immunology - Immunopathology, tissue immunology
35500 Allergy
36001 Medical and clinical microbiology - General and methods
36002 Medical and clinical microbiology - Bacteriology
BIOSYSTEMATIC CODES:
86215 Hominidae |
RELATED HOW DO I...? SOLUTIONS
NEED HELP?
Contact the Dialog Knowledge Center
Within North America 1 800 3 DIALOG (334 2564)
Outside North America 00 800 33 DIALOG (33 34 2564)
Web Form www.dialog.com/contacts/webform
|
You are viewing the
Click below to view the
 |
